Pipeline An expanding portfolio Aquestive Therapeutics is the undisputed leader in developing and delivering medications via film, through PharmFilm® technology. Building on this success, we have established a robust portfolio of treatments for CNS disorders and are advancing a late-stage pipeline with promising treatments for complex conditions. Reinventing medicines Our investigational medicines can offer simple new ways for patients and caregivers to use proven and trusted molecules. Our late-stage pipeline includes several investigational treatments for CNS conditions, where patients face great difficulty in using medication because of the impact of their disease.1 Looking ahead, we see even greater potential for PharmFilm® technology to improve patient treatment and are working to deliver complex molecules, proteins, and peptides on oral film with newer prodrugs and technologies. Product Pipeline Click for details Program Molecule Targeted Indication CNS Programs LIBERVANTTM* (Seeking Partner Outside US) diazepam† Breakthrough Seizures / Cluster Seizures Filed Complex Molecule Programs AQST-108 epinephrine† Anaphylaxis, severe allergy Phase 1 AQST-109 epinephrine† Anaphylaxis, severe allergy Phase 1 AQST-305 octreotide† Acromegaly / Carcinoid syndrome Pre-Clinical/Proof of Concept Licensed programs SUBOXONE® (Partner: Indivior) buprenorphine / naloxone Marketed since 2010 ZUPLENZ® (Partner: Hypera Brazil) ondansetron Marketed since 2010 KYNMOBITM (Partner: Sunovion) apomorphine† Approved since 2020 EXSERVANTM (EU Partner: Zambon; US Partner: Mitsubishi Tanabe) riluzole Licensed since 2019 AQST-119 (Partner: IntelGenx) tadalafil† Filed *Aquestive has received conditional acceptance of the use of this trade name, which is subject to final FDA review and acceptance †Subject to review, evaluation, and approval of the FDA Essential information for the investment community Keep current with Aquestive Aquestive sponsored clinical trials Learn More Clinical trial news and other updates Visit the newsroom References 1. Holsti M, Dudley N, Schunk J, et al. Intranasal midazolam vs rectal diazepam for the home treatment of acute seizures in pediatric patients with epilepsy. Arch Pediatr Adolesc Med. 2010;164(8):747–753. 2. Fischer D, Vander Leek TK, Ellis AK, Kim H. Anaphylaxis. Allergy Asthma Clin Immunol. 2018;14(Suppl 2):54 3. Wood RA, Camargo CA Jr, Lieberman P, et al. Anaphylaxis in America: the prevalence and characteristics of anaphylaxis in the United States. J Allergy Clin Immunol. 2014 Feb;133(2):461-467. 4. Ma L, Danoff TM, Borish L. Case fatality and population mortality associated with anaphylaxis in the United States. J Allergy Clin Immunol. 2014;133(4):1075-1083. SYMPAZAN® is a registered trademark of Aquestive Therapeutics, Inc. SUBOXONE® is a registered trademark of Indivior UK Ltd. ZUPLENZ® is a registered trademark of Midatech Pharma US Inc. DIASTAT® is a registered trademark of Bausch Health Companies, Inc. KYNMOBITM is a trademark of Sunovion Pharmaceuticals, Inc. Contact Us About Us Our Medicines Pipeline Innovative Drug Delivery Collaborations Investors Careers Newsroom Images of individuals were purchased by Aquestive® Therapeutics and are intended to model real patient scenarios. © 2020 Aquestive Therapeutics, Inc. PharmFilm®, Sympazan®, and the Aquestive logo are registered trademarks of Aquestive Therapeutics, Inc. All rights reserved. Terms of Use Privacy Policy Corporate Governance Code of Conduct California Compliance Declaration California Consumer Privacy Policy Sitemap This site uses cookies to store information on your computer. Some are essential to make our site work; others help us improve the user experience. By using the site, you consent to the placement of these cookies. OkLearn More